
Aziz Burgy
Partner
Experienced Hatch-Waxman Patent Litigator
As a first-chair trial attorney for major brand and generic drug companies in over 80 Hatch-Waxman Act cases, Aziz Burgy brings a wealth of experience to pharmaceutical patent litigation. He also advises clients with product selection to help them target products for acquisition or development. Aziz is consistently recognized by leading publications for his legal prowess, including Chambers, IAM Patent 1000, LMG Life Sciences, and Benchmark Litigation. He has also been honored among the top 3% of ANDA litigators in Patexia intelligence reports.
Aziz Burgy
Partner
Experienced Hatch-Waxman Patent Litigator
As a first-chair trial attorney for major brand and generic drug companies in over 80 Hatch-Waxman Act cases, Aziz Burgy brings a wealth of experience to pharmaceutical patent litigation. He also advises clients with product selection to help them target products for acquisition or development. Aziz is consistently recognized by leading publications for his legal prowess, including Chambers, IAM Patent 1000, LMG Life Sciences, and Benchmark Litigation. He has also been honored among the top 3% of ANDA litigators in Patexia intelligence reports.

Clients rely on Aziz to lead complex litigation in U.S. district courts, the Federal Circuit, the U.S. Court of Federal Claims, the Patent Trial and Appeal Board (PTAB), and the U.S. International Trade Commission (ITC) on their behalf. They value his ability to leverage his in-house experience and technical perspective to provide strategic guidance on FDA-related issues. Clients call Aziz an “excellent counselor and litigator” who has a “great strategic vision” and “sees the bigger picture” while crafting “creative arguments” on their behalf in litigation.
Aziz has also influenced patent-related legislation by advising Congress on the America Invents Act’s (AIA) impact on industries in which his clients operate, including the pharmaceutical, medical device, biotechnology, banking, Internet security robotics software, and GPS technology sectors.
A frequent speaker on patent, copyright, trademark, and Hatch-Waxman Act issues, Aziz has guest lectured courses on patent law domestically at University of North Carolina at Chapel Hill and George Mason University, and internationally at National Tsing Hua University. He was a board member for the University of North Carolina (UNC) Department of Biology, where he served as a liaison to faculty, students, and alumni. He proudly supports nonprofit organizations serving indigent persons and children with intellectual disabilities in Northern Virginia and has successfully represented Afghans seeking asylum on a pro bono basis.
Before attending law school, Aziz worked as a research associate at MedImmune, Inc., a leading biotechnology company. During his time there, Aziz worked on the development of a humanized monoclonal antibody (palivizumab) with activity against respiratory syncytial virus and a vaccine consisting of self-assembling, virus-like particles for the prevention of human papillomavirus (HPV) infection of the genital tract and associated cervical cancer.
Experience
- Novo Nordisk Inc. v. Alvogen Inc. (22-cv-00299, D. Del.)
Representing Alvogen in a patent infringement action filed by Novo Nordisk Inc. and Novo Nordisk A/S. The suit initially involved four patents and 26 claims. - Salix Pharmaceuticals Ltd. et al v. Norwich Pharmaceuticals Inc. (20-cv-00430, D. Del.)
Represented Norwich Pharmaceuticals Inc. in a patent infringement action filed by Salix Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Bausch Health Ireland Ltd., and Alfasigma S.P.A. The suit sought to estoppel Norwich from gaining approval to market a rifaximin 550 mg tablet, a generic of Salix’s Xifaxan®. Obtained judgment of invalidity on asserted claims, which halted the trading of the plaintiff’s parent company stock after it dropped more than 50% following the decision. - Alcon Inc. v. Alembic Pharmaceuticals Ltd. et al. (22-cv-00299, D. Del.)
Represented Alembic Pharmaceuticals Ltd. and Alembic Pharmaceuticals Inc. in a case in which Alcon Inc. and Alcon Laboratories Inc. asserted two patents relating to Alembic’s ANDA product, an ophthalmic solution containing olopatadine hydrochloride used to treat symptoms of ocular allergies. - Cosette Pharmaceuticals Inc. v. Azurity Pharmaceuticals Inc. (23-cv-0018, D. Del.)
Lead counsel to Cosette in a Hatch-Waxman suit against Azurity Pharmaceuticals Inc. involving Cosette’s vancomycin hydrochloride product. Secured total victory and consent judgment on all six asserted patents. - iCeutica Pty Ltd. et al. v. Novitium Pharma LLC (No. 18-cv-599-CFC, D. Del.)
Represented generic drug manufacturer Novitium in Hatch-Waxman litigation involving multiple patents for meloxicam, Vivlodex®. Secured dismissal based on noninfringement, resulting in favorable settlement for Novitium. Defended depositions of two 30(b)(6) corporate witnesses. - AstraZeneca AB et al v. Alembic Pharmaceuticals Ltd. et al. (1:20-cv-00202-RGA, D. Del.)
Represented Alembic in a lawsuit filed by AstraZeneca involving the generic version of the drug, Tagrisso®. - Merck Sharp & Dohme Corp. v. Anchen Pharmaceuticals Inc. and Par Pharmaceutical Inc (C.A. No. 1:19-cv-00311-RGA, D. Del.)
Secured favorable settlement for Anchen and Par Pharmaceutical in one of the largest Hatch-Waxman cases in the District of Delaware. The case, filed by Merck Sharp & Dohme Corp., involved the generic version of Janumet XR®. - Merck Sharp & Dohme Corp. v. Wockhardt Bio AG and Wockhardt USA LLC (C.A. No. 1:19-cv-00321-RGA, D. Del.)
Secured favorable settlement for Wockhardt in a lawsuit filed by Merck Sharp & Dohme Corp. relating to the generic version of Janumet IR® and Januvia®. - Taro Pharmaceutical Industries Ltd., Taro Pharmaceuticals North America Inc., and Taro Pharmaceuticals U.S.A. Inc. v. Novitium Pharma LLC (3:19-cv-01028-FLW-LHG, D.N.J.)
Secured favorable settlement for Novitium in a lawsuit filed by Taro Pharmaceutical Industries Ltd., Taro Pharmaceuticals North America Inc., and Taro Pharmaceuticals U.S.A. Inc. relating to the generic version of Ovide®.
Honors
- Benchmark Litigation, D.C. Litigation Star: Intellectual Property (2020 – 2026)
- Chambers USA, District of Columbia: Intellectual Property: Litigation (2026)
- IAM Patent 1000, World’s Leading Patent Professionals (2020 – 2025)
- Lawdragon, “500 Leading Global IP Lawyers” (2025 – 2026)
- Lawdragon, “500 Leading Lawyers in America” (2026)
- Lawdragon, “500 Leading Litigators in America” (2023; 2025 – 2026)
- LMG Life Sciences, Life Sciences Star (2020 – 2025)
- World Intellectual Property Review Leaders (2025)
- Thomson Reuters Stand-Out Lawyers – independently rated lawyers (2026)
- ANDA Litigation Intelligence Report, Best Performing ANDA Attorneys Representing Defendants (2021)
- ANDA Litigation Intelligence Report, Top 100 Most Active ANDA Attorneys (2021)
- ANDA Litigation Intelligence Report, Top ANDA Litigator (2020)
- Super Lawyers, Intellectual Property (2020 – 2025)
Education
- JD, magna cum laude – University of New Hampshire School of Law (2003); Editor, IDEA: The Journal of Law and Technology
- MS, Biotechnology – Johns Hopkins University (2000)
- BS, Biology – University of North Carolina at Chapel Hill (1996)
Admissions
- District of Columbia
- Maryland
- U.S. Court of Appeals for the Federal Circuit
- U.S. Court of Federal Claims
- U.S. District Court District of Columbia
- U.S. District Court District of Maryland
- U.S. District Court Northern District of Ohio
- U.S. Patent and Trademark Office
Quotes
Aziz is an exceptional attorney with great strategic vision. He is thoughtful, calm and decisive.
Chambers USA
[Aziz Burgy] is a highly experienced patent litigator with an in-depth knowledge of the generic pharmaceutical industry. He is very knowledgeable, responsive, and excellent to work with.
IAM Patent 1000
…known for his work on pharmaceutical patent litigation,…Aziz is an excellent counselor and litigator who sees the big picture and advances his clients' goals through hard work, responsiveness, and creative advocacy.
Chambers USA
News & Insights
News & Insights
The Skinny Line Between Possible and Plausible
Axinn Viewpoints
Intellectual Property
Axinn Expands Chambers USA Rankings Across Practices and Individuals in 2026 Guide
News
Antitrust
Axinn Recognized in 2026 IAM Patent 1000 for Patent Litigation Excellence
Awards & Recognitions
Intellectual Property
2026 FDLI Annual Conference
Speaking Engagement
Intellectual Property
ACI 22nd Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
Squires Again Broadens Discretion for Post-Grant Proceedings
Axinn Viewpoints
Intellectual Property
Back to the Well: FDA’s Draft Guidance on New Clinical Investigation Exclusivity
Axinn Viewpoints
Intellectual Property
Lawdragon Names 10 Axinn Partners to 500 Leading Lawyers in America 2026
Awards & Recognitions
Axinn Partners Ranked in the 2026 Edition of Benchmark Litigation
Awards & Recognitions
Litigation & Trials
ACI 5th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
Speaking Engagement





